[The main results of clinical trials of the efficacy, safety and pharmacokinetics of the perspective anti-tuberculosis drug makozinone (PBTZ169)].

Andrei Mariandyshev Alexander L Khokhlov S V Smerdin Victoria Shcherbakova O V Igumnova I V Ozerova A A Bolgarina N A Nikitina

Published in: Terapevticheskii arkhiv (2020)

One of the most promising and currently studied drugs-inhibitors of DprE1, a new target for the cell wall of mycobacteria, is PBTZ169 or macozinone, which is being develop by the Russian pharmaceutical company NEARMEDIC PLUS ltd.

Keyphrases

cell wall
clinical trial
mycobacterium tuberculosis
adverse drug
drug induced
hiv aids
pulmonary tuberculosis
open label
randomized controlled trial
emergency department
double blind
phase iii
hiv infected